Total Payments
$1.1M
2024 Payments
$162,753
Companies
70
Transactions
3,285
Medicare Patients
21,156
Medicare Billing
$25.4M
Payment Breakdown by Category
Other$738,440 (68.4%)
Consulting$185,422 (17.2%)
Travel$77,957 (7.2%)
Food & Beverage$60,850 (5.6%)
Research$15,088 (1.4%)
Education$1,199 (0.1%)
Gifts$58.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $672,992 | 349 | 62.4% |
| Consulting Fee | $185,422 | 83 | 17.2% |
| Travel and Lodging | $77,957 | 519 | 7.2% |
| Honoraria | $65,209 | 29 | 6.0% |
| Food and Beverage | $60,850 | 2,247 | 5.6% |
| Unspecified | $15,088 | 9 | 1.4% |
| Education | $1,199 | 46 | 0.1% |
| Grant | $239.52 | 1 | 0.0% |
| Gift | $58.59 | 2 | 0.0% |
Payments by Type
General
$1.1M
3,276 transactions
Research
$15,088
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $160,586 | 394 | $0 (2023) |
| UCB, Inc. | $122,931 | 340 | $0 (2024) |
| ABBVIE INC. | $117,708 | 365 | $0 (2024) |
| Amgen Inc. | $111,123 | 291 | $0 (2024) |
| Celgene Corporation | $71,880 | 103 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $67,641 | 103 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $46,367 | 100 | $0 (2024) |
| Horizon Therapeutics plc | $40,667 | 131 | $0 (2023) |
| Radius Health, Inc. | $38,238 | 98 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $36,951 | 96 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $162,753 | 403 | Amgen Inc. ($38,971) |
| 2023 | $124,416 | 345 | Amgen Inc. ($22,904) |
| 2022 | $140,241 | 395 | Amgen Inc. ($26,115) |
| 2021 | $57,747 | 271 | AbbVie Inc. ($14,461) |
| 2020 | $84,099 | 296 | Lilly USA, LLC ($20,547) |
| 2019 | $191,415 | 562 | Lilly USA, LLC ($49,077) |
| 2018 | $192,944 | 543 | Lilly USA, LLC ($44,339) |
| 2017 | $125,401 | 470 | Celgene Corporation ($30,782) |
All Payment Transactions
3,285 individual payment records from CMS Open Payments — Page 1 of 132
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $26.03 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/25/2024 | Bioventus LLC | DUROLANE (Device) | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: ORTHOPEDICSORTHOPEDIC SURGERY | ||||||
| 12/21/2024 | Fresenius Kabi USA, LLC | Tyenne (Biological) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: Biosimilars | ||||||
| 12/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: Immunology | ||||||
| 12/21/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.63 | General |
| 12/21/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: RESPIRATORY | ||||||
| 12/20/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $8.78 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/19/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | Cash or cash equivalent | $181.48 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $30.55 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $2.51 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Biocon Biologics Inc | — | — | Cash or cash equivalent | $1,681.08 | Research |
| Study: DEVOTE | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $121.81 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $10.05 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: IMMUNOLOGY | ||||||
| 12/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Immunology | ||||||
| 12/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Immunology | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $144.55 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Endocrinology | ||||||
| 12/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DEVOTE | Biocon Biologics Inc | $9,348 | 7 |
| A PHASE 3 MULTICENTER STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $5,741 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 5,471 | 757,776 | $39.1M | $7.8M |
| 2022 | 29 | 5,737 | 611,215 | $32.2M | $6.3M |
| 2021 | 29 | 5,326 | 458,452 | $25.9M | $5.8M |
| 2020 | 29 | 4,622 | 427,114 | $22.4M | $5.5M |
Total Patients
21,156
Total Services
2,254,557
Medicare Billing
$25.4M
Procedure Codes
118
All Medicare Procedures & Services
118 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 62 | 42,715 | $6.6M | $1.4M | 21.7% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 106 | 99,940 | $7.3M | $1.0M | 14.2% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 53 | 241,200 | $5.8M | $943,703 | 16.3% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 36 | 165,017 | $2.5M | $774,595 | 31.3% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 108 | 24,908 | $6.3M | $635,727 | 10.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 356 | 33,721 | $1.9M | $620,974 | 32.9% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 60 | 76,243 | $1.5M | $605,847 | 39.7% |
| J0491 | Injection, anifrolumab-fnia, 1 mg | Office | 2023 | 17 | 42,630 | $2.1M | $550,082 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 850 | 3,972 | $850,008 | $364,792 | 42.9% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 12 | 4,500 | $987,750 | $284,972 | 28.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 337 | 2,127 | $1.3M | $215,760 | 16.9% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 343 | 738 | $284,868 | $55,149 | 19.4% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 855 | 856 | $231,976 | $31,954 | 13.8% |
| 73721 | Mri scan of leg joint without contrast | Office | 2023 | 139 | 174 | $157,818 | $27,633 | 17.5% |
| 72148 | Mri scan of lower spinal canal without contrast | Office | 2023 | 175 | 178 | $108,046 | $26,609 | 24.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 446 | 2,202 | $110,078 | $24,353 | 22.1% |
| 73221 | Mri scan of arm joint without contrast | Office | 2023 | 99 | 120 | $108,840 | $19,550 | 18.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 128 | 786 | $234,600 | $17,224 | 7.3% |
| J7322 | Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | Office | 2023 | 21 | 1,130 | $233,996 | $14,737 | 6.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 73 | 228 | $136,800 | $11,425 | 8.4% |
| 72195 | Mri scan of pelvis without contrast | Office | 2023 | 59 | 59 | $43,247 | $10,842 | 25.1% |
| 72141 | Mri scan of upper spinal canal without contrast | Office | 2023 | 67 | 67 | $41,272 | $10,036 | 24.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 436 | 11,483 | $115,270 | $9,666 | 8.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 67 | 68 | $19,443 | $8,174 | 42.0% |
| 20604 | Aspiration and/or injection of fluid from small joint using ultrasound guidance | Office | 2023 | 83 | 123 | $44,895 | $7,629 | 17.0% |
About Dr. Joy Schechtman, DO
Dr. Joy Schechtman, DO is a Rheumatology healthcare provider based in Peoria, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649244716.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joy Schechtman, DO has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $162,753 received in 2024. These payments were reported across 3,285 transactions from 70 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($672,992).
As a Medicare-enrolled provider, Schechtman has provided services to 21,156 Medicare beneficiaries, totaling 2,254,557 services with total Medicare billing of $25.4M. Data is available for 4 years (2020–2023), covering 118 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Peoria, AZ
- Active Since 02/15/2006
- Last Updated 08/23/2025
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1649244716
Products in Payments
- Otezla (Drug) $107,389
- Cimzia (Drug) $103,669
- TALTZ (Drug) $78,789
- ACTHAR (Biological) $78,160
- OFEV (Drug) $51,782
- TAVNEOS (Drug) $42,931
- Tymlos (Biological) $37,862
- KRYSTEXXA (Biological) $37,665
- SAPHNELO (Biological) $36,051
- RINVOQ (Biological) $35,670
- SIMPONI ARIA (Biological) $33,649
- RAYOS (Drug) $32,907
- COSENTYX (Biological) $27,800
- XELJANZ (Drug) $26,398
- ORENCIA (Biological) $21,923
- OLUMIANT (Drug) $19,157
- TREMFYA (Drug) $17,899
- Bimzelx (Biological) $16,249
- Tavneos (Drug) $16,122
- SKYRIZI (Biological) $13,278
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Peoria
Vaughn Hanna, Md, MD
Rheumatology — Payments: $52,945
Rheumatology $52,945
Orwah Al-Khalili, Md, MD
Rheumatology — Payments: $16,847
Rheumatology $16,847
Maryah Mansoor, Md, MD
Rheumatology — Payments: $8,405
Rheumatology $8,405
Dr. Shriram Lokare, M.d, M.D
Rheumatology — Payments: $5,509
Rheumatology $5,509
Mr. Varun Bhalla, M.d, M.D
Rheumatology — Payments: $4,161
Rheumatology $4,161
Sarah Saeed, M.d, M.D
Rheumatology — Payments: $2,933
Rheumatology $2,933